Peptide Atlas · Peptide

Pemvidutide

Pemvidutide is a GLP-1 and glucagon dual receptor agonist; in a 12-week randomized trial in 94 people with metabolic dysfunction-associated steatotic liver disease, weekly injections cut liver fat by 46.6% to 68.5% from baseline against 4.4% on placebo.

emerging

provisional
1 citation
0 discussions
0 followers
ALT-801

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Pemvidutide. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Pemvidutide reduced liver fat content over 12 weeks in MASLD (RCT, n=94)	emerging	pmid 39002641

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.